2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemia
2023
A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults
Luskin M, Murakami M, Keating J, Winer E, Garcia J, Stahl M, Wadleigh M, Flamand Y, Neuberg D, Galinsky I, Leonard R, Hagopian E, Weizer C, McLanahan C, Stone R, Wang E, Stock W, DeAngelo D. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. Blood 2023, 142: 965. DOI: 10.1182/blood-2023-174246.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaDose-limiting toxicityMaximum tolerated doseStem cell transplantationPhase I studyCML-LBCDose escalationAllogeneic stem cell transplantationBCR-ABL1-positive acute lymphoblastic leukemiaCell line xenograft modelsPatient-derived xenograft modelsBlast phase CMLEscalating daily dosesPhase 2 doseLymphoid blast crisisBiomarkers of responseDurability of responseChronic myeloid leukemiaABL1 inhibitorsDose expansionEscalating dosesBlast crisisDeep remissionExpansion cohortTolerated dose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply